48 results about "Cholemia" patented technology

The present application provides a variety of salts of 25HC3S, including crystalline salts of 25HC3S. Provided herein are pharmaceutical formulations of the salts of the invention, and methods of treating or preventing diseases therewith, the diseases such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), alcoholic hepatitis, acute kidney injury (AKI), psoriasis, atherosclerosis, hypercholesterolemia, hypertriglyceridemia, alcoholic fatty liver disease (AFLD), alcoholic steatohepatitis (ASH), leptin resistance, leptin deficiency, diabetic conditions, autoimmune conditions, inflammatory conditions, and the like. Nervous system disorders, EB virus related growth, and disorders associated with fat accumulation and inflammation. Methods of making the salts of the present application are also provided.

The present invention provides methods for treating patients suffering from familial hypercholesterolemia, including both HeFH and HoFH. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to ANGPTL3 in combination with a therapeutically effective amount of a statin, a first lipid lowering agent other than a statin, and a second lipid lowering agent other than a statin. The first non-statin lipid lowering agent is an agent that inhibits cholesterol uptake (e.g. ezetimibe) and the second non-statin lipid-lowering agent is an inhibitor of microsomal triglyceride transfer protein (e.g. lomitapide). The combination therapy is useful in treating hypercholesterolemia, as well as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, chylomicronemia, and to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor, such as cardiovascular diseases.

The present disclosure relates to methods of administering thyroid hormone receptor agonists. The present disclosure provides methods wherein the methods maintain the activity of a given thyroid receptor agonist in ameliorating or curing obesity, hyperlipidemia, hypercholesterolemia, diabetes, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, hypothyroidism, and related conditions, meanwhile, thyroid-related and thyroid axis-related side effects are reduced or eliminated.

Disclosed is a method of lowering elevated cholesterol plasma levels in a subject. Also disclosed is a method of treating hypercholesterolemia in a subject. The methods comprise administering to the subject in the absence of a cholesterol lowering drug an effective amount of Compound 1 or pharmaceutically acceptable salt thereof.

The application discloses a liver-targeted gene editing system based on endogenous promoter hijacking and application, and belongs to the field of biological medicine. The system is composed of an LNP-wrapped modified Cas nuclease mRNA (first component) and a promoter-free viral vector carrying a therapeutic transgene donor (second component). The system uses LNP to realize the transient burst expression of Cas nuclease in the liver, mediates the generation of double-strand breaks at the site of endogenous high-expression genes, induces the site-specific integration of therapeutic transgenes without exogenous promoters, and hijacks the expression driven by endogenous promoters by using the splice acceptor (SA) mechanism. The application solves the risk of carcinogenesis caused by random integration of exogenous strong promoters and the immunotoxicity of long-term expression of nucleases through a "double safety lock" design. Experimental results prove that the system has high editing efficiency, long-term stability and no off-target, and can be used for various liver-derived metabolic diseases such as hemophilia, hypercholesterolemia and the like.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

Compositions and methods are described herein for treating subjects having hypercholesterolemia and / or cardiovascular disease.

The present application provides a novel thyroid hormone β receptor agonist of formula (I) having better activity, selectivity or safety and the use thereof for preventing or treating diseases related to the action of β receptor agonists, including, for example, obesity, hyperlipidemia, hypercholesterolemia, diabetes, liver diseases (fatty liver, NASH, NAFLD, etc.), cardiovascular diseases (atherosclerosis, etc.), thyroid diseases (hypothyroidism, thyroid cancer, etc.), and the like.

The invention relates to application of guaiacol or a derivative thereof in preparation of a medicine for preventing or treating metabolic syndrome, and belongs to the technical field of medicines. The guaiacol and the derivative thereof provided by the invention have the advantages that by regulating a fat metabolism pathway, the insulin resistance condition is obviously improved, the inflammatory response and oxidative stress injury are relieved, and the prevention and treatment on the metabolism-related fatty liver disease (MASLD), hyperlipidemia, hypercholesteremia, obesity and diabetes mellitus are realized through the synergistic effect of multiple dimensions.

Disclosed are compounds of Formula I as well as pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

Disclosed are compounds of Formula I: wherein A, B, D, X, R1, R2 and R8 are as defined herein, or salts thereof, which have the properties of antagonizing PCSK9. Also described are pharmaceutical formulations comprising the compounds of Formula I, or salts thereof, and methods of treating cardiovascular diseases and conditions associated with PCSK9 activity, such as atherosclerosis, hypercholesterolemia, coronary heart disease, metabolic syndrome, acute coronary syndrome, or associated cardiovascular diseases and cardiovascular metabolic conditions.

The application relates to application of guaiacol or a derivative thereof in preparation of a medicine for preventing or treating metabolic syndrome, and belongs to the technical field of medicines. The guaiacol and the derivative thereof provided by the application can significantly improve insulin resistance conditions by regulating a fat metabolism channel, and can simultaneously reduce inflammatory reaction and oxidative stress damage, and can realize prevention and treatment of metabolic associated steatohepatitis (MASLD), hyperlipidemia, hypercholesterolemia, obesity and diabetes through synergistic action in multiple dimensions.

Prenylated tetrahydroquinolines and quinolines and pharmaceutical compositions comprising the same. Prenylated tetrahydroquinoline and quinolines and pharmaceutical compositions comprising the same, for use in the prevention and / or treatment of peroxisome proliferator-activated receptor (PPAR)-mediated diseases such as metabolic syndrome, type 2 diabetes mellitus, dyslipidemia, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, obesity, dyslipidemic atherosclerosis, metabolic dysfunction- associated fatty liver disease (MAFLD), cardiovascular disease, cardiometabolic disease, neurodegenerative disease, Friedreich's ataxia, Parkinson's disease, multiple sclerosis, Alzheimer's disease, autoimmune disease, rheumatoid arthritis, autoimmune thyroid disease, dermatological disease, and cancer.

Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

A method of reducing elevated plasma levels of cholesterol in a subject is disclosed. Also disclosed is a method of treating hypercholesterolemia in a subject. The method comprises administering to the subject an effective amount of Compound 1, or a pharmaceutically acceptable salt thereof, in the absence of a cholesterol-lowering drug.

Provided herein are recombinant phage, probiotic vaccines and therapeutics comprising recombinant phage; and related methods of using same. In some embodiments, it includes recombinant phage (e.g., filamentous) and / or probiotic vaccines comprising a recombinant filamentous phage genome; and therapeutic methods of using the invention recombinant phage and / or probiotic vaccines. The invention recombinant filamentous phage: probiotic vaccines comprising said recombinant phage are useful wherein, for example, in therapeutic methods for preventing, treating, and / or reducing the risk of cancer, autoimmune diseases, respiratory diseases (e.g., asthma), neurological diseases, infectious diseases, among other diseases (osteoporosis, elevated cholesterol, among others).

A compound represented by structural formula (I) and a pharmaceutically acceptable salt thereof and a pharmaceutical composition comprising the compound or the pharmaceutically acceptable salt thereof, can be used for treating diseases such as obesity, hyperlipidemia, hypercholesterolemia, and diabetes and also for treating other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other related disorders and diseases

The invention belongs to the technical field of dermatan sulfate application, and particularly relates to application of dermatan sulfate in promotion of cholesterol excretion. The cholesterol excretion promoting effect of dermatan sulfate is discussed through in-vivo and in-vitro experiments, and results show that dermatan sulfate has the effect of promoting cholesterol excretion of liver cells, not only can reduce blood fat and liver lipid and promote excretion of cholesterol to excrement, but also can inhibit expression of ASGR1, further up-regulates LXR alpha, and has the effect of promoting cholesterol excretion of liver cells. The expression of ABCA1 and ABCG5 transporters is improved to promote cholesterol excretion and reduce the in-vivo lipid level. Therefore, dermatan sulfate is a potential medicine for promoting cholesterol excretion, a new thought is provided for development of a targeted ASGR1 medicine for promoting cholesterol excretion, and a theoretical basis is provided for treatment of cardiovascular diseases such as hypercholesterolemia and the like.

The invention relates to a pharmaceutical combination comprising: a first conjugate comprising at least one effector molecule and a single-domain antibody (sdAb) for binding to a first cell-surface molecule; and comprising a saponin, a derivative thereof, or a second conjugate comprising a binding molecule for binding to a second cell-surface molecule and the saponin and / or the derivative thereof, wherein the saponin or the derivative thereof is a monodesmosidic or bidesmosidic triterpene glycoside. The invention also relates to a composition comprising the first conjugate and the saponin (derivative) or the second conjugate comprising the saponin (derivative). In addition, the invention relates to a pharmaceutical combination or composition of the invention, for use as a medicament, and for use in the treatment or the prophylaxis of a cancer, an auto-immune disease such as rheumatoid arthritis, an enzyme deficiency, a gene defect, a disease relating to a gene defect, an amyloidosis, a disease related to an enzyme deficiency, an infection such as a viral infection, hypercholesterolemia, primary hyperoxaluria, haemophilia A, haemophilia B, alpha-1 antitrypsin related liver disease, acute hepatic porphyria, transthyretin-mediated amyloidosis. Furthermore, the invention relates to an in vitro or ex vivo method for transferring the first conjugate of the invention from outside a cell to inside said cell, preferably to the cytosol of said cell.

The invention discloses application of a substance for promoting an IDH3A level in preparation of related products for treating hypercholesterolemia. According to the present invention, the IDH3A overexpression adeno-associated virus 8 (IDH3A-AAV8) is constructed for the first time, and the IDH3A-AAV8 can specifically improve the expression level of the IDH3A gene in the liver so as to effectively reduce the plasma total cholesterol level of the hypercholesterolemia model mouse, improve the liver lipid deposition and finally achieve the effective treatment of the hypercholesterolemia; meanwhile, the correlation between the IDH3A and the hypercholesteremia is disclosed for the first time, and it is proved that the hypercholesteremia can be effectively treated by improving IDH3A gene expression or enhancing IDH3A protein activity.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

Provided are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

This invention provides saponin derivatives with improved therapeutic concentration ranges. [Solution] The present invention relates to a saponin-based saponin derivative comprising a triterpene aglycone and a first glycan and / or a second glycan, wherein the saponin derivative comprises: an aglycone core structure containing a derivatized aldehyde group; and / or the first glycan, wherein the first glycan contains a derivatized carboxyl group; and / or the second glycan, wherein the second glycan contains at least one derivatized acetoxy group. The present invention also provides use in the treatment or prevention of cancer, infectious diseases, viral infections, hypercholesterolemia, primary hyperoxaluria, hemophilia A, hemophilia B, alpha-1 antitrypsin-related liver disease, acute hepatic porphyria, transthyretin-mediated amyloidosis, or autoimmune diseases.

The invention belongs to the field of biological medicines, and relates to oligonucleotide targeting PCSK9mRNA or pre-mRNA and application of the oligonucleotide in preparation of medicines for preventing or treating diseases or symptoms related to hypercholesteremia.

Provided are compounds of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), metabolic dysfunction-associated steatohepatitis (MASH), hepatic fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, to a patient in need thereof.

Invented are compounds of formula Iand the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.

The present application relates to a kind of synthesis method and application of betaine-derived carbon quantum dots, first, betaine and amaranth red are used to generate carbon quantum dots stock solution by hydrothermal reaction, the stock solution is filtered, dialysis, freeze-drying, and carbon quantum dots powder is obtained.Second, a certain concentration range of carbon quantum dots solution is configured, and the antioxidant enzyme activity of betaine-derived carbon quantum dots is detected.Then, with zebra fish hypercholesterolemia model as an example, betaine-derived carbon quantum dots solution is applied to the treatment of zebra fish hypercholesterolemia model, and the mouse hyperlipidemia model is verified.Finally, in hepatocyte system, it is found that betaine-derived carbon quantum dots are through inhibiting PCSK9 to play the role of lowering blood lipid.The present application is not only an antioxidant enzyme with catalase activity, but also can reduce total cholesterol and total triglyceride in hypercholesterolemia by inhibiting PCSK9, and relieve liver steatosis.It has higher use value and application prospect.

Disclosed herein are antisense compounds and methods for decreasing LDL-C in an individual having elevated LDL-C. Additionally disclosed are antisense compounds and methods for treating, preventing, or ameliorating hypercholesterolemia and / or atherosclerosis. Further disclosed are antisense compounds and methods for decreasing coronary heart disease risk. Such methods include administering to an individual in need of treatment an antisense compound targeted to a PCSK9 nucleic acid. The antisense compounds administered include gapmer antisense oligonucleotides.

This disclosure provides crystalline forms of a compound of Formula (I), as well as pharmaceutically acceptable compositions thereof, and methods for their preparation and use in methods of treating hypercholesterolemia and other conditions related to PCSK9 activity, e.g., atherosclerosis, atherosclerotic cardiovascular disease, peripheral arterial disease, cerebrovascular disease, coronary heart disease, metabolic syndrome, acute coronary syndrome, or related cardiovascular disease and cardiometabolic conditions.